KRAS — Targeted Therapies, Trials & Pipeline
The most frequently mutated oncogene in human cancer; a rapidly expanding target space beyond G12C.
Approved drugs targeting KRAS
Adagrasib
·
Sotorasib
Investigational pipeline agents
avutometinib
·
BBO-11818
·
BBO-8520
·
BEBT-607
·
BGB-53038
·
BI 1823911
·
BI 3706674
·
BLU-924
·
BPI-460372
·
Calderasib
·
D3S-001
·
daraxonrasib
·
Darlifarnib
·
defactinib
·
Divarasib
·
ELI-002 7P
·
Elironrasib
·
Garsorasib
·
GFH375
·
Glecirasib
·
HRS-4642
·
INCB161734
·
JAB-23E73
·
KRAS-mutant TCR-engineered T cells with GRT-C903/GRT-R904 vaccine
·
LY3962673
·
LY4066434
·
mKRAS-VAX
·
MRTX1133
·
Olomorasib
·
Pelareorep
·
PF-07934040
·
RMC-4630
·
Setidegrasib
·
Zoldonrasib
Landmark trials
CodeBreaK 200
·
KRYSTAL-1